Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Bioavailability of HRG2010 in Healthy Subjects
NCT06976346Phase 1Completed
- Sponsor
- Hengrui
- Start
- Sep 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HRG2010(II) in Parkinson's disease (PD) (4 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration, Area Under the Plasma Concentration-Time Curve from Time 0 to Last Quantifiable Concentration and 2 more. Started Sep 2021; status: completed.
02
Drugs
HRG2010(II)
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06976346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06976346.